Updating results

6680 results Sort: Relevance | Date

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

This guidance has been withdrawn

Technology appraisal guidance Published June 2017 Withdrawn

Oral health in care homes (QS151)

Evidence-based statements to deliver quality improvements in oral health, including dental health and daily mouth care, for adults in care homes

Quality standard Published June 2017

Haematological cancers (QS150)

Evidence-based statements to deliver quality improvements in managing haematological cancers (cancer of the blood, bone marrow or lymph nodes) in all age groups

Quality standard Published June 2017

Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults

Technology appraisal guidance Published May 2017

Osteoporosis (QS149)

Evidence-based statements to deliver quality improvements in managing osteoporosis in adults, including assessing risk and preventing fragility fractures

Quality standard Published April 2017

Sexually transmitted infections: condom distribution schemes (NG68)

Evidence-based recommendations on condom distribution schemes to help reduce sexually transmitted infections (STIs) in all populations and prevent

NICE guideline Published April 2017

Vitamin D: increasing supplement use in at-risk groups (PH56)

Evidence-based recommendations on increasing Vitamin D supplement use in at-risk groups

Public health guideline Published November 2014 Last updated May 2017

Respiratory conditions

This interactive flowchart covers the guidance NICE has produced on airway problems, cystic fibrosis, mesothelioma, obstructive sleep apnoea-hypopnoea syndrome, persistent air leaks and respiratory failure. It also includes links to NICE

NICE Pathway Published June 2015 Last updated June 2017

Blood and bone marrow cancers

This interactive flowchart includes guidance on leukaemia and improving outcomes for people with blood and bone marrow cancers.To find other information about blood and bone marrow cancers, including evidence from NICE Accredited sources, visit NICE

NICE Pathway Published December 2013 Last updated May 2017

Transcutaneous microwave ablation for severe primary axillary hyperhidrosis

Interventional procedures guidance In consultation

Blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia [ID1008]

In development [GID-TA10119] Expected publication date: 24 October 2018

Technology appraisal guidance In development

Violence and aggression

In development [GID-QS10022] Expected publication date: 21 June 2017

Quality standard In development

NGR-TNF for previously treated advanced malignant pleural mesothelioma (ID655)

In development [GID-TA10183] Expected publication date: 27 June 2018

Technology appraisal guidance In development

Pertuzumab for adjuvant treatment of early HER2-positive breast cancer (ID1192)

In development [GID-TA10184] Expected publication date: 25 July 2018

Technology appraisal guidance In development

Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (ID1173)

In development [GID-TA10182] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for treating recurrent or metastatic squamous cell head and neck cancer (ID1140)

In development [GID-TA10181] Expected publication date: 25 July 2018

Technology appraisal guidance In development

Developmental follow-up of children and young people born preterm

In development [GID-CGWAVE0752] Expected publication date: 09 August 2017

NICE guideline In development

Early and locally advanced breast cancer (update)

In development [GID-NG10016] Expected publication date: 17 July 2018

NICE guideline In development

Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]

In development [GID-TA10028] Expected publication date: TBC

Technology appraisal guidance In development

Hearing loss (adult presentation)

In development [GID-CGWAVE0833] Expected publication date: 16 May 2018

NICE guideline In development

Processed nerve allograft to repair peripheral nerve discontinuities

Interventional procedures guidance In consultation

Leukaemia (chronic myeloid, acute lymphoblastic) - ponatinib [ID671]

In development [GID-TA10060] Expected publication date: 28 June 2017

Technology appraisal guidance In development

Venetoclax for chronic lymphocytic leukaemia [ID944]

In development [GID-TA10077] Expected publication date: 06 September 2017

Technology appraisal guidance In development

Cabozantinib for treating renal cell carcinoma [ID931]

In development [GID-TA10075] Expected publication date: 09 August 2017

Technology appraisal guidance In development

Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma [ID959]

In development [GID-TA10103] Expected publication date: TBC

Technology appraisal guidance In development

Tocilizumab for treating giant cell arteritis [ID1051]

In development [GID-TA10172] Expected publication date: 25 April 2018

Technology appraisal guidance In development

Multimorbidity

In development [GID-QS10023] Expected publication date: 21 June 2017

Quality standard In development

Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

In development [GID-TA10179] Expected publication date: TBC

Technology appraisal guidance In development

Metreleptin for treating lipodystrophy (ID861)

In development [GID-HST10011] Expected publication date: 26 September 2018

Highly specialised technologies guidance In development

Idiopathic pulmonary fibrosis - pirfenidone (review TA282) [ID837]

In development [GID-TAG504] Expected publication date: 12 July 2017

Technology appraisal guidance In development

Termination of pregnancy

NICE guideline In consultation

Kidney transplantation (children, adolescents) - immunosuppressive regimens (review of TA99) [ID346]

In development [GID-TAG255] Expected publication date: 11 October 2017

Technology appraisal guidance In development

Uveitis (non-infectious) - adalimumab and dexamethasone [ID763]

In development [GID-TA10007] Expected publication date: 26 July 2017

Technology appraisal guidance In development

Sirukumab for previously treated active rheumatoid arthritis (ID1002)

In development [GID-TA10180] Expected publication date: 30 May 2018

Technology appraisal guidance In development

Gaucher disease (type 1) - eliglustat [ID709]

In development [GID-GAUCHERDISEASETYPE1ELIGLUSTATID709] Expected publication date: 28 June 2017

Highly specialised technologies guidance In development

Avelumab for merkel cell carcinoma [ID1102]

In development [GID-TA10136] Expected publication date: 25 April 2018

Technology appraisal guidance In development

Persistent pain

In development [GID-NG10069] Expected publication date: 20 January 2020

NICE guideline In development

Reducing the mortality and morbidity for healthcare associated infections

In development [GID-NG10059] Expected publication date: TBC

NICE guideline In development

Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]

In development [GID-TA10158] Expected publication date: TBC

Technology appraisal guidance In development

Ocrelizumab for treating relapsing multiple sclerosis [ID937]

In development [GID-TA10152] Expected publication date: 25 July 2018

Technology appraisal guidance In development

Pembrolizumab for classical hodgkin lymphoma [ID1062]

In development [GID-TA10130] Expected publication date: 23 May 2018

Technology appraisal guidance In development

Cenegermin for treating neurotrophic keratitis [ID946]

In development [GID-TA10131] Expected publication date: 25 July 2018

Technology appraisal guidance In development

Hyperparathyroidism (primary): diagnosis, assessment and initial management

In development [GID-NG10051] Expected publication date: 23 May 2019

NICE guideline In development

Biotin for treating progressive multiple sclerosis [ID919]

In development [GID-TA10099] Expected publication date: 22 August 2018

Technology appraisal guidance In development

Cerebral palsy in adults

In development [GID-NG10031] Expected publication date: 15 January 2019

NICE guideline In development

Binimetinib for treating melanoma [ID833]

In development [GID-TA10074] Expected publication date: TBC

Technology appraisal guidance In development

Short bowel syndrome - teduglutide [ID885]

In development [GID-TA10048] Expected publication date: 25 April 2018

Technology appraisal guidance In development

Carfilzomib for treated multiple myeloma [ID934]

In development [GID-TA10005] Expected publication date: 19 July 2017

Technology appraisal guidance In development

Oesophago-gastric cancer

In development [GID-CGWAVE0801] Expected publication date: 01 January 2018

NICE guideline In development